Abstract

Evaluation of the Stability of Ketoprofen in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-use Date

Author(s): Peacock Gina F, Sauvageot Jurgita, Addo Richard T

Issue: Jul/Aug 2014 - Volume 18, Number 4

Page(s): 348-350

Download in electronic PDF format for $75
  • Evaluation of the Stability of Ketoprofen in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-use Date Page 1
  • Evaluation of the Stability of Ketoprofen in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-use Date Page 2
  • Evaluation of the Stability of Ketoprofen in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-use Date Page 3

Note: Electronic version includes errata or revisions.

Abstract

Previous reports indicate that pharmacists are assigning a wide variety of beyond-use dates to extemporaneously compounded medications in topical Pluronic lecithin organogel. The objective of this study was to evaluate the stability of ketoprofen in Pluronic lecithin organogel over a period of six months and to determine an appropriate beyond-use date for this formulation. A stability-indicating high-performance liquid chromatography method for ketoprofen in Pluronic lecithin organogel was validated in our laboratory. Samples of the formulation were analyzed by high-performance liquid chromatography at 0, 7, 14, 21, 28, 45, 60, 90, and 180 days. At each time point, the average concentration and average percent of initial concentration were calculated. The beyond-use date was determined as the time period that the samples were physically stable and maintained at least 90% of the initial concentration. Ketoprofen in Pluronic lecithin organogel was chemically and physically stable for six months when stored at room temperature and protected from light. Therefore, a beyond-use date of six months is appropriate for this preparation.

Related Keywords

  • ketoprofen
  • Pluronic lecithin organogel
  • topical preparations
  • transdermal vehicle
  • stability
  • beyond-use dates
  • formulations

Related Categories

  • EXCIPIENTS
  • PEER-REVIEWED
  • STABILITIES, COMPATIBILITIES
  • ALLERGY/IMMUNOLOGY/INFLAMMATION
  • DOSAGE FORMS/DRUG CARRIERS
  • STORAGE

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Jul/Aug 2014
Pg. 348-350
Evaluation of the Stability of Ketoprofen in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-use Date
Author(s): Peacock Gina F, Sauvageot Jurgita, Addo Richard T
Jul/Aug 2014
Pg. 345-347
Evaluation of the Stability of Promethazine Hydrochloride in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-use Date
Author(s): Peacock Gina F, Sauvageot Jurgita
May/Jun 2014
Pg. 253-255
Evaluation of the Stability of Fluoxetine in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-use Date
Author(s): Peacock Gina F, Sauvageot Jurgita
May/Jun 2014
Pg. 256-261
Preparation and In Vitro Evaluation of a Pluronic Lecithin Organogel Containing Ricinoleic Acid for Transdermal Delivery
Author(s): Boddu Sai HS, Bonam Sindhu Prabha, Wei Yangjie, Alexander Kenneth
Jan/Feb 2021
Pg. 73-81
Beyond-use Date of Trimix: A Reproducible Stability Study Using Bracketing Design
Author(s): Patel Gopesh, Davis Countaney, Liu Yi, Ip Kendice, Debideen Krystal E, Anderson Stephanie, Byrne Robert, Herr Dylan, Rhoads Melissa Merrell, Caputo Ross, Banov Daniel, Bassani August S
Nov/Dec 2010
Pg. 522-525
Stability of Methimazole in Poloxamer Lecithin Organogel to Determine Beyond-Use Date
Author(s): Pignato Alyssa, Pankaskie Marvin, Birnie Christine
May/Jun 2012
Pg. 248-252
In Vitro Percutaneous Absorption of Ketoprofen and Testosterone: Comparison of Pluronic Lecithin Organogel vs. Pentravan Cream
Author(s): Lehman Paul A, Raney Sam G
Sep/Oct 2012
Pg. 428-430
Evaluation of the Stability of Acetaminophen in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-Use Date
Author(s): Peacock Gina F, Sauvageot Jurgita
Jan/Feb 2022
Pg. 65-71
Physical Stability and Release Profile of Compounded Gabapentin Containing Pluronic Lecithin Organogel for Neuropathic Pain Management
Author(s): Hong Eun Ji, Sumanasekera Wasana, Le Uyen Minh
May/Jun 2013
Pg. 247-253
Effect of Formulation pH on Transdermal Penetration of Antiemetics Formulated in Poloxamer Lecithin Organogel
Author(s): Woodall Rachel, Arnold John J, McKay Doug, Abill C Scott
Jan/Feb 2016
Pg. 81-85
Evaluation of the Stability of Mercaptopurine Suspension Compounded in a Commercial Vehicle and the Determination of an Appropriate Beyond-use Date
Author(s): Peacock Gina F, Sauvageot Jurgita, Hill Ashley, Killian Alyssa
Mar/Apr 2017
Pg. 164-170
Development and Application of a High-Performance Liquid Chromatography Stability-Indicating Assay for Beyond-Use Date Determination of Compounded Topical Gels Containing Multiple Active Drugs
Author(s): Gorman Gregory, Sokom Simara, Coward Lori, Arnold John J
May/Jun 2005
Pg. 242-246
Bioavailability of Promethazine in a Topical Pluronic Lecithin Organogel: A Pilot Study
Author(s): Glisson James K, Wood Rebecca L, Kyle Patrick B, Cleary John D
Jul/Aug 2018
Pg. 319
Ketoprofen 10% in Pluronic Lecithin Organogel
Author(s): Allen Loyd V Jr
Nov/Dec 2010
Pg. 513
Baclofen 5%, Capcaicin 0.075%, Ketoprofen 10%, and Tetracaine 2% in Pluronic Lecithin Organogel
Author(s): Allen Loyd V Jr
Nov/Dec 2012
Pg. 471-474
Beyond-use Date: Establishment and Maintenance
Author(s): Osteen Richard
Jan/Feb 2019
Pg. 52
Ketoprofen 10% in Pluronic Lecithin Organogel
Author(s): Allen Loyd V Jr
Mar/Apr 2019
Pg. 150
Ketoprofen 10% in Pluronic Lecithin Organogel
Author(s): Allen Loyd V Jr
Nov/Dec 2010
Pg. 512
Amitriptyline Hydrochloride 2%, Baclofen 5%, Ketamine Hydrochloride 5%, Ketoprofen 10% in Pluronic Lecithin Organogel
Author(s): Allen Loyd V Jr
May/Jun 2011
Pg. 245
Ketoprofen 10%, Ibuprofen 10%, Cyclobenzaprine Hydrochloride 2%, and Piroxicam 2% in Pluronic Lecithin Organogel Gel
Author(s): Allen Loyd V Jr